Márton Vajna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Márton Vajna has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Romána Zelkó
University Pharmacy Department of Pharmacy Administration, Semmelweis University, 7-9 Hőgyes Street, 1092 Budapest, Hungary
2 shared publications - Adrienn Kazsoki
University Pharmacy Department of Pharmacy Administration, Semmelweis University, Hőgyes Endre Street 7-9, H-1092 Budapest, Hungary
1 shared publication - Andrea Fekete
MTA-SE Lendület “Momentum” Diabetes Research Group, 1083 Budapest, Hungary
1 shared publication - Andrea Guba
Proteomics Core Facility, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Egyetem tér 1, 4032 Debrecen, Hungary
1 shared publication - Anita Csorba
Department of Ophthalmology, Semmelweis University, Budapest, Hungary
1 shared publication - Anna Takácsi‐Nagy
Department of Innovation, PannonPharma Ltd., PannonPharma út 1., 7720 Pécsvárad, Hungary
1 shared publication
Latest Publications
- Open Access
- 9 October 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (10) , 1600
Formulation Development of a pH-Adjusted, Preservative-Free 1% 5-Fluorouracil Eye Drop Compounded from Injectable Concentrate: A Risk-Assessed Magistral Formulation and 28-Day Stability Case Study
Background: No licensed ophthalmic 5-fluorouracil (5-FU) product is available in Hungary, and published compounded 5-FU eye drops are alkaline dilutions of the injectable concentrate. We report a formulation development and 28-day storage-stability case study of a pH-adjusted, preservative-free 1% 5-FU eye drop prepared under Council of Europe Resolution CM/Res(2016)1. Methods: Five injectable concentrates were characterised for pH, and one was titrated with 0.1 N hydrochloric acid in a preservative-free ophthalmic vehicle to pH 7.30–7.60. Three 10 mL batches were prepared aseptically and release-tested; drop volume and delivered dose were determined on one batch, which was also followed for 28 days at 15–25 °C and 2–8 °C by inspection, pH, sterility and comparative HPLC-UV assay (single determinations). Results: All concentrates were alkaline (pH 8.95–9.18). The selected formulation reached pH 7.43; individual doses (mean 0.435 mg per drop) were within ±8% of the mean. At 15–25 °C, samples remained clear and sterile, with pH 7.41–7.51 and assay ≥ 97% of initial, without directional trend. At 2–8 °C, precipitate formed from day 7 and the supernatant assay fell to 89.1% by day 28. Conclusions: The preparation remained within specification for 28 days at controlled room temperature but not under refrigeration, consistent with, though not proven to result from, the lower solubility of un-ionised 5-FU. The 28-day period is provisional, not a validated shelf-life; in-use stability, osmolality and viscosity were not established.
- 9 October 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (10) , 1600
Open AccessFormulation Development of a pH-Adjusted, Preservative-Free 1% 5-Fluorouracil Eye Drop Compounded from Injectable Concentrate: A Risk-Assessed Magistral Formulation and 28-Day Stability Case Study
Background: No licensed ophthalmic 5-fluorouracil (5-FU) product is available in Hungary, and published compounded 5-FU eye drops are alkaline dilutions of the injectable concentrate. We report a formulation development and 28-day storage-stability case study of a pH-adjusted, preservative-free 1% 5-FU eye drop prepared under Council of Europe Resolution CM/Res(2016)1. Methods: Five injectable concentrates were characterised for pH, and one was titrated with 0.1 N hydrochloric acid in a preservative-free ophthalmic vehicle to pH 7.30–7.60. Three 10 mL batches were prepared aseptically and release-tested; drop volume and delivered dose were determined on one batch, which was also followed for 28 days at 15–25 °C and 2–8 °C by inspection, pH, sterility and comparative HPLC-UV assay (single determinations). Results: All concentrates were alkaline (pH 8.95–9.18). The selected formulation reached pH 7.43; individual doses (mean 0.435 mg per drop) were within ±8% of the mean. At 15–25 °C, samples remained clear and sterile, with pH 7.41–7.51 and assay ≥ 97% of initial, without directional trend. At 2–8 °C, precipitate formed from day 7 and the supernatant assay fell to 89.1% by day 28. Conclusions: The preparation remained within specification for 28 days at controlled room temperature but not under refrigeration, consistent with, though not proven to result from, the lower solubility of un-ionised 5-FU. The 28-day period is provisional, not a validated shelf-life; in-use stability, osmolality and viscosity were not established.
- Open Access
- 3 February 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (2) , 260
UHPLC-MS-Based Analysis of Fluvoxamine in Rabbit Aqueous Humour and Serum: Method Development and Validation
Background/Objectives: Fluvoxamine (FLU) is a selective serotonin reuptake inhibitor and one of the most potent agonists of the sigma-1 receptor. Emerging evidence shows that FLU exerts protective effects in multiple organs, making it a promising candidate for topical ocular therapy. Developing an FLU eyedrop for glaucoma can address a significant treatment gap with potentially fewer side effects compared with conventional therapies. To optimise formulation development, precise quantification of FLU in ocular compartments such as aqueous humour, as well as systemic circulation, is essential to characterise drug absorption, ocular bioavailability, and safety. Methods: We developed and validated a UHPLC-MS method for FLU detection in aqueous humour and serum using simple sample preparation steps. Results: The 11-min-long reverse phase chromatography followed by SRM-based mass spectrometry detection provides a highly selective and sensitive FLU detection method. Our method was proved to be linear in the 0.0625–1.5 µg/mL range and was validated according to the EMA guidelines. Conclusions: The simplicity of sample preparation, the tolerable matrix effects, and the favourable detection parameters provide a robust tool for preclinical pharmacokinetic and pharmacodynamic studies of FLU’s ocular protective effects.
- 3 February 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (2) , 260
Open AccessUHPLC-MS-Based Analysis of Fluvoxamine in Rabbit Aqueous Humour and Serum: Method Development and Validation
Background/Objectives: Fluvoxamine (FLU) is a selective serotonin reuptake inhibitor and one of the most potent agonists of the sigma-1 receptor. Emerging evidence shows that FLU exerts protective effects in multiple organs, making it a promising candidate for topical ocular therapy. Developing an FLU eyedrop for glaucoma can address a significant treatment gap with potentially fewer side effects compared with conventional therapies. To optimise formulation development, precise quantification of FLU in ocular compartments such as aqueous humour, as well as systemic circulation, is essential to characterise drug absorption, ocular bioavailability, and safety. Methods: We developed and validated a UHPLC-MS method for FLU detection in aqueous humour and serum using simple sample preparation steps. Results: The 11-min-long reverse phase chromatography followed by SRM-based mass spectrometry detection provides a highly selective and sensitive FLU detection method. Our method was proved to be linear in the 0.0625–1.5 µg/mL range and was validated according to the EMA guidelines. Conclusions: The simplicity of sample preparation, the tolerable matrix effects, and the favourable detection parameters provide a robust tool for preclinical pharmacokinetic and pharmacodynamic studies of FLU’s ocular protective effects.
- Open Access
- 28 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (3) , 1623
A Comparative Pharmacokinetic Study for Cysteamine-Containing Eye Drops as an Orphan Topical Therapy in Cystinosis
Cystinosis is a low-prevalence lysosomal storage disease. The pathomechanism involves abnormal functioning of the cystinosine lysosomal cystine transporter (CTNS), causing intraliposomal accumulation of the amino acid cysteine disulfide, which crystallizes and deposits in several parts of the body. The most common ophthalmic complication of cystinosis is the deposition of “gold dust” cystine crystals on the cornea, which already occurs in infancy and leads to severe photosensitivity and dry eyes as it gradually progresses with age. In the specific treatment of cystinosis, preparations containing cysteamine (CYA) are used. The availability of commercialized eyedrops for the targeted treatment is scarce, and only Cystadrops® are commercially available with strong limitations. Thus, magistral CYA-containing compounded eyedrops (CYA-CED) could have a key role in patient care; however, a rationally designed comprehensive study on the commercialized and magistral products is still missing. This work aims to build up a comprehensive study about commercialized and magistral CYA eye drops, involving pharmacokinetic and physicochemical characterization (applying mucoadhesivity, rheology test, investigation of drug release, and parallel artificial membrane permeability assays), as well as ex vivo tests, well supported by statistical analysis.
- 28 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (3) , 1623
Open AccessA Comparative Pharmacokinetic Study for Cysteamine-Containing Eye Drops as an Orphan Topical Therapy in Cystinosis
Cystinosis is a low-prevalence lysosomal storage disease. The pathomechanism involves abnormal functioning of the cystinosine lysosomal cystine transporter (CTNS), causing intraliposomal accumulation of the amino acid cysteine disulfide, which crystallizes and deposits in several parts of the body. The most common ophthalmic complication of cystinosis is the deposition of “gold dust” cystine crystals on the cornea, which already occurs in infancy and leads to severe photosensitivity and dry eyes as it gradually progresses with age. In the specific treatment of cystinosis, preparations containing cysteamine (CYA) are used. The availability of commercialized eyedrops for the targeted treatment is scarce, and only Cystadrops® are commercially available with strong limitations. Thus, magistral CYA-containing compounded eyedrops (CYA-CED) could have a key role in patient care; however, a rationally designed comprehensive study on the commercialized and magistral products is still missing. This work aims to build up a comprehensive study about commercialized and magistral CYA eye drops, involving pharmacokinetic and physicochemical characterization (applying mucoadhesivity, rheology test, investigation of drug release, and parallel artificial membrane permeability assays), as well as ex vivo tests, well supported by statistical analysis.